Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan plus toripalimab as neoadjuvant therapy for resectable stage IIIA–IIIB (N2) NSCLC
ChiCTR2600116542Phase 2Not yet recruiting
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in non-small cell lung cancer (NSCLC), sponsored by General Hospital of Eastern Military Command. Primary endpoint: Pathological complete response rate (pCR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116542.